A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry)

Background and study aims: The hemostatic powder TC-325 (Hemospray; Cook Medical, Winston-Salem, North Carolina, USA) has shown promising results in the treatment of upper gastrointestinal bleeding (UGIB) in expert centers in pilot studies. The aim of this study was to evaluate the feasibility and efficacy of TC-325 in a large prospective registry of use in routine practice.

Patients and methods: The data of all patients treated with TC-325 were prospectively collected through a national registry. Outcomes were the immediate feasibility and efficacy of TC-325 application, as well as the rates of rebleeding at Day 8 and Day 30. Multivariate analysis was performed to determine predictive factors of rebleeding.

Results: A total of 202 patients were enrolled and 64 endoscopists participated from 20 centers. TC-325 was used as salvage therapy in 108 patients (53.5 %). The etiology of bleeding was an ulcer in 75 patients (37.1 %), tumor in 61 (30.2 %), postendoscopic therapy in 35 (17.3 %), or other in 31 (15.3 %). Application of the hemostatic powder was found to be very easy or easy in 31.7 % and 55.4 %, respectively. The immediate efficacy rate was 96.5 %. Recurrence of UGIB was noted at Day 8 and Day 30 in 26.7 % and 33.5 %, respectively. Predictive factors of recurrence at Day 8 were melena at initial presentation and use of TC-325 as salvage therapy.

Conclusion: These multicenter data confirmed the high rate of immediate hemostasis, excellent feasibility, and good safety profile of TC-325, which could become the treatment of choice in bleeding tumors or postendoscopic bleeding but not in bleeding ulcers where randomized studies are needed.

Trial registration: ClinicalTrials.gov (NCT02595853)

^* These authors contributed equally to this work.

• References

• 1 Hearnshaw SA, Logan RFA, Lowe D et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335
• 2 Lau JYW, Barkun A, Fan D et al. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013; 381: 2033-2043
• 3 Lu Y, Loffroy R, Lau JYW et al. Multidisciplinary management strategies for acute non-variceal upper gastrointestinal bleeding. Br J Surg 2014; 101: e34-e50
• 4 Chung IK, Kim EJ, Lee MS et al. Endoscopic factors predisposing to rebleeding following endoscopic hemostasis in bleeding peptic ulcers. Endoscopy 2001; 33: 969-975
• 5 Barkun A, Sabbah S, Enns R et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-1246
• 6 Barkun AN, Moosavi S, Martel M. Topical hemostatic agents: a systematic review with particular emphasis on endoscopic application in GI bleeding. Gastrointest Endosc 2013; 77: 692-700
• 7 Holster IL, van Beusekom HMM, Kuipers EJ et al. Effects of a hemostatic powder hemospray on coagulation and clot formation. Endoscopy 2015; 47: 638-645
• 8 Sung JJY, Luo D, Wu JCY et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
• 9 Smith LA, Stanley AJ, Bergman JJ et al. Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the survey to evaluate the application of hemospray in the luminal tract. J Clin Gastroenterol 2014; 48: e89-e92
• 10 Smith LA, Morris AJ, Stanley AJ. The use of hemospray in portal hypertensive bleeding; a case series. J Hepatol 2014; 60: 457-460
• 11 Leblanc S, Vienne A, Dhooge M et al. Early experience with a novel hemostatic powder used to treat upper GI bleeding related to malignancies or after therapeutic interventions (with videos). Gastrointest Endosc 2013; 78: 169-175
• 12 Chen Y-I, Barkun AN, Soulellis C et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
• 13 Jacques J, Legros R, Chaussade S et al. Endoscopic haemostasis: an overview of procedures and clinical scenarios. Dig Liver Dis 2014; 46: 766-776
• 14 Kim Y-I, Choi IJ, Cho S-J et al. Outcome of endoscopic therapy for cancer bleeding in patients with unresectable gastric cancer. J Gastroenterol Hepatol 2013; 28: 1489-1495
• 15 Sheibani S, Kim JJ, Chen B et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther 2013; 38: 144-150
• 16 Holster I, Kuipers E, Tjwa E. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2012; 45: 63-66
• 17 Chen Y-I, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015; 47: 167-171
• 18 Bakman Y, Freeman ML. Update on biliary and pancreatic sphincterotomy. Curr Opin Gastroenterol 2012; 28: 420-426
• 19 Facciorusso A. Endoscopic submucosal dissection vs endoscopic mucosal resection for early gastric cancer: a meta-analysis. World J Gastrointest Endosc 2014; 6: 555
• 20 Guo H-M. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol 2014; 20: 5540
• 21 Komeda Y, Bruno M, Koch A. EMR is not inferior to ESD for early Barrett’s and EGJ neoplasia: an extensive review on outcome, recurrence and complication rates. Endosc Int Open 2014; 02: E58-E64
• 22 Napoléon B, Gincul R, Ponchon T et al. Endoscopic papillectomy for early ampullary tumors: long-term results from a large multicenter prospective study. Endoscopy 2014; 46: 127-134
• 23 Palma GDD. Endoscopic papillectomy: indications, techniques, and results. World J Gastroenterol 2014; 20: 1537
• 24 Pellisé M, Desomer L, Burgess NG et al. The influence of clips on scars after EMR: clip artifact. Gastrointest Endosc 2016; 83: 608-616
• 25 Moosavi S, Chen Y, Barkun A. TC-325 application leading to transient obstruction of a post-sphincterotomy biliary orifice. Endoscopy 2013; 45: E130-E130
• 26 Tarantino I, Barresi L, Granata A et al. Hemospray for arterial hemorrhage following endoscopic ultrasound-guided pseudocyst drainage. Endoscopy 2014; 46: E71-E71
• 27 Yau AHL, Ou G, Galorport C et al. Safety and efficacy of Hemospray^® in upper gastrointestinal bleeding. Can J Gastroenterol Amp Hepatol 2014; 28: 72-76
• 28 Curcio G, Granata A, Traina M. Hemospray for multifocal bleeding following ultra-low rectal endoscopic submucosal dissection. Dig Endosc 2014; 26: 606-607
• 29 Appleby VJ, Hutchinson JM, Beckett CJ et al. Use of the haemostatic agent TC-325 in the treatment of bleeding secondary to endoscopic retrograde cholangiopancreatography sphincterotomy. QJM 2015; 108: 79-80
• 30 Ivekovic H, Bilic B, Markos P et al. Successful use of Hemospray to control refractory post-polypectomy bleeding. Endoscopy 2015; 47: E466-467
• 31 Kim KB, Yoon SM, Youn SJ. Endoscopy for nonvariceal upper gastrointestinal bleeding. Clin Endosc 2014; 47: 315
• 32 Masci E, Arena M, Morandi E et al. Upper gastrointestinal active bleeding ulcers: review of literature on the results of endoscopic techniques and our experience with Hemospray. Scand J Gastroenterol 2014; 49: 1290-1295
• 33 de Groot N, van Oijen M, Kessels K et al. Reassessment of the predictive value of the Forrest classification for peptic ulcer rebleeding and mortality: can classification be simplified?. Endoscopy 2013; 46: 46-52